Work

Abstract P2-08-03: Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer

Year: 2017

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs16-p2-08-03

Authors: AM DeMichele, AS Clark, R Holmes, M Volpe, C Medrano, A Troxel, K Fox, S Domchek, J Matro, A Bradbury, N Shih, M Feldman, E Hexner, J Bromberg

Institutions: Memorial Sloan Kettering Cancer Center, University of Pennsylvania

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2593304604

Cites:

Cited by:

Related to: 10